The year in cardiovascular medicine 2021: dyslipidaemia.

Tokgozoglu, Lale; Orringer, Carl; Ginsberg, Henry N; Catapano, Alberico L

Tokgozoglu, Lale; Orringer, Carl; Ginsberg, Henry N; Catapano, Alberico L.

Afiliação

Tokgozoglu L; Department of Cardiology, Hacettepe University Faculty of Medicine, Sihhiye, 06100 Ankara, Turkey.
Orringer C; Department of Preventive Cardiovascular Medicine, Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL, USA.
Ginsberg HN; Department of Medicine, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Catapano AL; Department of Pharmacological and Biomolecular Sciences, University of Milan and IRCCS Multimedica, Milano, Italy.

Eur Heart J ; 43(8): 807-817, 2022 02 22.

Article em En | MEDLINE | ID: mdl-34974612

Assuntos

Fármacos Cardiovasculares; Doenças Cardiovasculares; Dislipidemias; Fármacos Cardiovasculares/uso terapêutico; LDL-Colesterol; Dislipidemias/tratamento farmacológico; Humanos

Palavras-chave

Antisense; CRISPR; Cardiovascular diseases; LDL-C. Triglycerides; Lipids; Lp(a); Nucleic acid therapeutics; PCSK9 inhibitors; RNA interference; Statins

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Cardiovasculares / Doenças Cardiovasculares / Dislipidemias Limite: Humans Idioma: En Revista: Eur Heart J Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google